White Willow Bark for Fever Management

Insufficient evidence 1 studies

Research suggests that white willow bark, as a source of salicylate compounds, raises particular safety concerns in the context of fever management for certain populations, notably breastfeeding mothers and infants. The available evidence on this specific application comes from a single 2006 review entry from the LactMed database, which is a relatively narrow evidence base from which to draw broad conclusions. Studies indicate that salicylates from willow bark pass into breast milk in amounts that increase disproportionately with higher doses, and that high-dose exposure has been linked to metabolic acidosis in at least one breastfed infant, with an unknown but theoretically possible risk of Reye's syndrome during viral illness. The overall direction of this literature is cautionary rather than supportive for fever management use, and the limited scope of available research — consisting of a single pharmacokinetic and safety review rather than clinical trials — means that conclusions about efficacy or broader population safety remain largely unestablished.

Related studies

Citations from PubMed and preprint sources. Match score (0-100) reflects automated search ranking, not clinical appraisal.

Title Type Year Direction Match
Willow Bark. Review 2006 Mixed 72

← Back to White Willow Bark

Medical Disclaimer: Noyemi provides information from published research for educational purposes only. This content is not medical advice and does not replace consultation with a qualified healthcare provider. Always consult your doctor before starting, stopping, or changing any supplement regimen, especially if you take medications or have existing health conditions.